BicycleTx Ltd

Cambridge,
United Kingdom
https://www.bicycletherapeutics.com

Booth: 33165

Home
Products

Products

Zelenectide pevedotin

Zelenectide pevedotin is composed of a highly selective Nectin-4–targeted bicyclic peptide, connected to an MMAE cytotoxic payload via a cleavable linker. Upon binding to Nectin-4, MMAE is released by proteases in the tumor microenvironment, triggering tumor cell death and tumor regression. Zelenectide pevedotin is designed to have rapid distribution to tumor cells for efficient delivery of MMAE into the tumor, and a short plasma half-life to limit prolonged overall systemic exposure and potential for AEs. The molecule is currently being evaluated in several clinical trials. The Phase I/II Duravelo-1 trial is studying zelenectide pevedotin in several Nectin-4 associated tumors, while the Phase II/III Duravelo-2 trial is studying zelenectide pevedotin as a treatment for metastatic urothelial cancer. Studies using NECTIN4 gene amplification as a biomarker for zelenectide pevedotin therapy stratification in breast, lung and other cancers are underway.
... More Info Less Info

BT5528

BT5528 targets the erythropoietin-producing hepatocellular A2 receptor (EphA2) with a clinical safety profile that is differentiated from previous drugs developed against this target, validating the potential for BDCs against both proven and challenging novel drug targets. The molecule is composed of EphA2 targeting Bicycle®, a valine-citrulline (val-cit) cleavable linker and a MMAE cytotoxin payload. BT5528 is currently being evaluated in a Phase I/II clinical trial as a monotherapy and in combination with IO agent. EphA2 IHC status for patients enrolled in the study are being recorded for future assessment as a potential predictor of efficacy.
... More Info Less Info

BicycleTx Ltd

Products

Categories

Contact this Exhibitor